management of chronic knee pain
TRANSCRIPT
![Page 1: Management of chronic knee pain](https://reader035.vdocuments.site/reader035/viewer/2022062523/5872dcee1a28ab74188b766d/html5/thumbnails/1.jpg)
Management of Chronic Knee Pain
Dr (Maj) Pankaj N SurangeMBBS, MD, FIPP(Hungary)
Director, Interventional Pain and Spine Centre, New DelhiChairman, WIP, India section
![Page 2: Management of chronic knee pain](https://reader035.vdocuments.site/reader035/viewer/2022062523/5872dcee1a28ab74188b766d/html5/thumbnails/2.jpg)
Cartilage• Forms the opposing articulating surface of Synovial joints
Low Friction Lubrication
Absorbs the
Mechanical Load
Painless smooth Movements
![Page 3: Management of chronic knee pain](https://reader035.vdocuments.site/reader035/viewer/2022062523/5872dcee1a28ab74188b766d/html5/thumbnails/3.jpg)
Collagen type -II
Proteoglycan
Hyaluronan(ECM)
Hyaluronan is an important component of articular cartilage, where it is present as a coat around each cell (chondrocyte). When aggrecan monomers bind to hyaluronan in the presence of link protein, large, highly negatively charged aggregates form. These aggregates imbibe water and are responsible for the resilience of cartilage (its resistance to compression).
![Page 4: Management of chronic knee pain](https://reader035.vdocuments.site/reader035/viewer/2022062523/5872dcee1a28ab74188b766d/html5/thumbnails/4.jpg)
• Articular Cartilage is Metabolically active but has limited capacity to replace damaged or lost cell
• Cartilage matrix surrounding a defect is antiadhesive- precursor cells are unable to attach themselves
• Being avascular---lacks the capacity to initiate cascade of cytokine production to attract repair cells
![Page 5: Management of chronic knee pain](https://reader035.vdocuments.site/reader035/viewer/2022062523/5872dcee1a28ab74188b766d/html5/thumbnails/5.jpg)
Injury and Repair
• Superficial Cartilage injuries –Do not heal because these lesion do not initiate inflammation.
• Deep cartilage and Subchondral bone injuries- hemorrhage, fibrin clot formation and inflammation---Repaired tissue is fibrocartilage
![Page 6: Management of chronic knee pain](https://reader035.vdocuments.site/reader035/viewer/2022062523/5872dcee1a28ab74188b766d/html5/thumbnails/6.jpg)
Pathophysiology –OA Knee
• Degenerative joint disease characterized by progressive loss of articular cartilage followed by attempted repair of articular cartilage, remodeling and sclerosis of subchondral bone and in many instances formation of subchondral bone cyst and osteophytes.
Subchondral bone responds with vascular invasion and increased cellularity, at areas of pressure
Loss of cartilage results in the loss of the joint space
![Page 7: Management of chronic knee pain](https://reader035.vdocuments.site/reader035/viewer/2022062523/5872dcee1a28ab74188b766d/html5/thumbnails/7.jpg)
Diagnosis
Clinical Radiological
![Page 8: Management of chronic knee pain](https://reader035.vdocuments.site/reader035/viewer/2022062523/5872dcee1a28ab74188b766d/html5/thumbnails/8.jpg)
Clinical Signs and Symptoms Pain
• Initially, it is typically aching in nature, related to joint use, and relieved by rest
MTF OA -anteromedial pain, mainly on walking.
PF OA causes localized anterior kneepain, worse on negotiating stairs/inclines, and a progressive aching on prolongedsitting that is relieved by standing and ‘stretching’ of the legs.
Posterior pain usually indicates a complicating popliteal cyst
![Page 9: Management of chronic knee pain](https://reader035.vdocuments.site/reader035/viewer/2022062523/5872dcee1a28ab74188b766d/html5/thumbnails/9.jpg)
As OA progresses, pain may become more persistent and
occur also at rest and at night.
Raised Intraosseous pressure secondary to venous obstruction
Bone marrow oedemaSynovitis
EnthesopathyBursitis
TendinitisLigamentous Strain
![Page 10: Management of chronic knee pain](https://reader035.vdocuments.site/reader035/viewer/2022062523/5872dcee1a28ab74188b766d/html5/thumbnails/10.jpg)
• Stiffness• from slowness of joint movement, to pain on initial
movement such as getting up from a chair• Early morning stifness with Synovitis or Enthesopathy
• Crepitus• May be palpable throughout the range of movement• In gross cases may be even audible
![Page 11: Management of chronic knee pain](https://reader035.vdocuments.site/reader035/viewer/2022062523/5872dcee1a28ab74188b766d/html5/thumbnails/11.jpg)
• Tenderness• Tenderness to palpation along the joint-line
(‘capsular/joint-line tenderness’) suggests a capsular/intracapsular origin of pain.
• Point tenderness away from the joint-line suggests a periarticular lesion;
inferior insertion of the medial collateral ligament.
![Page 12: Management of chronic knee pain](https://reader035.vdocuments.site/reader035/viewer/2022062523/5872dcee1a28ab74188b766d/html5/thumbnails/12.jpg)
• Deformity• Varus and Valgus Deformity• Popliteal cyst• Antalgic gait
![Page 13: Management of chronic knee pain](https://reader035.vdocuments.site/reader035/viewer/2022062523/5872dcee1a28ab74188b766d/html5/thumbnails/13.jpg)
• Swelling –Effusion• Patellar Displacement
![Page 14: Management of chronic knee pain](https://reader035.vdocuments.site/reader035/viewer/2022062523/5872dcee1a28ab74188b766d/html5/thumbnails/14.jpg)
Radiological Evaluation
• The plain radiograph remains a key investigation in the clinical management of OA. It is particularly useful for:
• diagnosis—showing characteristic structural changes typical of OA and• absence of features of alternative arthropathies (e.g., inflammatory
erosive disease);• assessment of the severity of structural change;• identification of associated chondrocalcinosis
• Limitations• The requirement of optimal views and techniques-Stress or loaded
views• insensitive for detection of early OA and minor progression of cartilage and bone change.• Plain radiographs are a static, not dynamic.
![Page 15: Management of chronic knee pain](https://reader035.vdocuments.site/reader035/viewer/2022062523/5872dcee1a28ab74188b766d/html5/thumbnails/15.jpg)
X-RayThe four main radiographic features of OA are joint-space
narrowing,subchondral sclerosis, subchondral cyst formation, and osteophyte
Postero-Anterior weight bearing views
Assessment of Joint Space, lateral subluxation and Varus/valgus deformity
![Page 16: Management of chronic knee pain](https://reader035.vdocuments.site/reader035/viewer/2022062523/5872dcee1a28ab74188b766d/html5/thumbnails/16.jpg)
![Page 17: Management of chronic knee pain](https://reader035.vdocuments.site/reader035/viewer/2022062523/5872dcee1a28ab74188b766d/html5/thumbnails/17.jpg)
Weight-bearing films in knee flexion
Demonstrate more narrowing than those in full extension, since the loadingis then on the part of the joint that is principally targeted by cartilage loss.
![Page 18: Management of chronic knee pain](https://reader035.vdocuments.site/reader035/viewer/2022062523/5872dcee1a28ab74188b766d/html5/thumbnails/18.jpg)
Lateral Radiograph
• marked loss of patellofemoral joint-space• femoral and superior patellar Osteophytes• anterior enthesophyte
Patellofemoral OA.
![Page 19: Management of chronic knee pain](https://reader035.vdocuments.site/reader035/viewer/2022062523/5872dcee1a28ab74188b766d/html5/thumbnails/19.jpg)
• Intercondylar Tibial or Femoral Central osteophytes
![Page 20: Management of chronic knee pain](https://reader035.vdocuments.site/reader035/viewer/2022062523/5872dcee1a28ab74188b766d/html5/thumbnails/20.jpg)
• Osteochondral Bodies
![Page 21: Management of chronic knee pain](https://reader035.vdocuments.site/reader035/viewer/2022062523/5872dcee1a28ab74188b766d/html5/thumbnails/21.jpg)
Skyline view
• complete joint-space loss• prominent grooving of the articular surfaces, • lateral patellar subluxation
![Page 22: Management of chronic knee pain](https://reader035.vdocuments.site/reader035/viewer/2022062523/5872dcee1a28ab74188b766d/html5/thumbnails/22.jpg)
doubtful JSN and possible osteophytic
lipping
definite osteophytes and possible
JSN
multiple osteophytes,definite JSN,
sclerosis, possible bony
deformity
large osteophytes, marked JSN,
severe sclerosisand definitely
bony deformity
![Page 23: Management of chronic knee pain](https://reader035.vdocuments.site/reader035/viewer/2022062523/5872dcee1a28ab74188b766d/html5/thumbnails/23.jpg)
MRI• Superficial cartilage loss even without narrowing• Bone marrow edema
![Page 24: Management of chronic knee pain](https://reader035.vdocuments.site/reader035/viewer/2022062523/5872dcee1a28ab74188b766d/html5/thumbnails/24.jpg)
• Three-dimension spoiled gradient recalled echo imaging with fat suppression (3D-SPGR) is the current standard for morphological imaging of cartilage
T2 mapping of articular cartilage
![Page 25: Management of chronic knee pain](https://reader035.vdocuments.site/reader035/viewer/2022062523/5872dcee1a28ab74188b766d/html5/thumbnails/25.jpg)
Management
![Page 26: Management of chronic knee pain](https://reader035.vdocuments.site/reader035/viewer/2022062523/5872dcee1a28ab74188b766d/html5/thumbnails/26.jpg)
Management of Osteoarthritis Knee-Non Pharmacological treatment
• Negative Approach• Exercises• Shock absorbing Insoles• Weight reduction • Patellar taping• Quadriceps Exercises
A high Q-angle causes the quadriceps to pull on the patella and leads to patellar tracking which is a predisposing factor for pain.
![Page 27: Management of chronic knee pain](https://reader035.vdocuments.site/reader035/viewer/2022062523/5872dcee1a28ab74188b766d/html5/thumbnails/27.jpg)
![Page 28: Management of chronic knee pain](https://reader035.vdocuments.site/reader035/viewer/2022062523/5872dcee1a28ab74188b766d/html5/thumbnails/28.jpg)
Pharmacological treatment
• Pharmacologic recommendations for the initial management of knee OA1. Acetaminophen2. Oral NSAIDs3. Topical NSAIDs4. Tramadol
• Negative recommendations for knee OA– Chondroitin sulfate– Glucosamine– Topical capsaicin
![Page 29: Management of chronic knee pain](https://reader035.vdocuments.site/reader035/viewer/2022062523/5872dcee1a28ab74188b766d/html5/thumbnails/29.jpg)
Recommendations for Glucosamine and Chondroitin
• The largest and best-designed clinical trial is the Glucosamine/chondroitin Arthritis Intervention Trial (GAIT)
• Neither glucosamine hydrochloride nor chondroitin sulfate has been shown to be more efficacious than placebo for the treatment of OA Knee
• Three months of treatment is a sufficient period for the evaluation of efficacy; if there is no clinically significant decrease in symptoms by this time, the supplements should be discontinued. Furthermore, there is no evidence that these agents prevent osteoarthritis in healthy persons or in persons with knee pain but normal radiographs
• Hochberg MC. Nutritional supplements for knee osteoarthritis—Still no resolution. New England Journal of medicine 354:848-850, 2006.
• Sawitzke AD and others. The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: A report from the Glucosamine/chondroitin Arthritis Intervention Trial. Arthritis & Rheumatism 58:3183-3191, 2008.
• Reichenbach S, and others. Meta-analysis: chondroitin for osteoarthritis of the knee or hip. Annals of Internal Medicine 146:580-590, 2007.
![Page 30: Management of chronic knee pain](https://reader035.vdocuments.site/reader035/viewer/2022062523/5872dcee1a28ab74188b766d/html5/thumbnails/30.jpg)
It is uncertain whether these compounds are absorbed intact, whether they are metabolized to any degree, and what role they actually play in vivo. Currently, there remains no theoretical or empirical evidence to support the original supposition that these compounds provide substrate for articular cartilage repair.
Recommendations for Glucosamine and Chondroitin
![Page 31: Management of chronic knee pain](https://reader035.vdocuments.site/reader035/viewer/2022062523/5872dcee1a28ab74188b766d/html5/thumbnails/31.jpg)
August 2014
![Page 32: Management of chronic knee pain](https://reader035.vdocuments.site/reader035/viewer/2022062523/5872dcee1a28ab74188b766d/html5/thumbnails/32.jpg)
• Knee Aspiration-ASAP
![Page 33: Management of chronic knee pain](https://reader035.vdocuments.site/reader035/viewer/2022062523/5872dcee1a28ab74188b766d/html5/thumbnails/33.jpg)
• Popliteal cyst Aspiration
![Page 34: Management of chronic knee pain](https://reader035.vdocuments.site/reader035/viewer/2022062523/5872dcee1a28ab74188b766d/html5/thumbnails/34.jpg)
• Intra-articular Corticosteroids
• Acute exacerbation of pain• Signs of inflammation
![Page 35: Management of chronic knee pain](https://reader035.vdocuments.site/reader035/viewer/2022062523/5872dcee1a28ab74188b766d/html5/thumbnails/35.jpg)
Joint Irrigation
• Removal of particulate debris from the joint space- loose bodies of cartilage and bone, calcium crystals
• Mobilizing phlogistic materials -degradative enzymes, cytokines from the joint.
![Page 36: Management of chronic knee pain](https://reader035.vdocuments.site/reader035/viewer/2022062523/5872dcee1a28ab74188b766d/html5/thumbnails/36.jpg)
• Aspiration or Injection• USG Guided Vs. Fluoroscopic Guided Vs. Blind
![Page 37: Management of chronic knee pain](https://reader035.vdocuments.site/reader035/viewer/2022062523/5872dcee1a28ab74188b766d/html5/thumbnails/37.jpg)
Viscosupplements
• High mw HA is viscoelastic
• Because of its HA content, joint fluid acts as a viscous lubricant during slow movement of the joint, as in walking, and as an elastic shock absorber during rapid movement, as in running.
• Synovial fluid HA lubricates the soft tissue and provides a surface layer on the articular cartilage.
• Other effects• it inhibits PGE-2 synthesis induced by interleukin-1• protects against proteoglycan (PG) depletion, and cytotoxicity
induced by oxygen-derived free radicals• suppresses cartilage matrix degradation by fibronectin fragmentsand• reduces leukocyte adherence, proliferation,migration, and
phagocytosis.3
![Page 38: Management of chronic knee pain](https://reader035.vdocuments.site/reader035/viewer/2022062523/5872dcee1a28ab74188b766d/html5/thumbnails/38.jpg)
• Altman, R.D., Hochberg, M.C., Moskowitz, R.W., and Schnitzer, T.J. (2000).Recommendations for the medical management of osteoarthritis of the hip and knee. Arthritis Rheum 43:1905–15.
The American College of Rheumatology Guidelines for the Medical Management of Osteoarthritis recommend the use of IA HA injections for treatment of joint pain in patients with knee OA who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics.
Viscosupplement-Evidence
![Page 39: Management of chronic knee pain](https://reader035.vdocuments.site/reader035/viewer/2022062523/5872dcee1a28ab74188b766d/html5/thumbnails/39.jpg)
Viscosupplement-Evidence
Clin Orthop Relat Res. 2007 Feb;455:113-22.Viscosupplementation for knee osteoarthritis: a systematic review.Divine JG, Zazulak BT, Hewett TE.
systematic review of the five published meta-analyses, which include single- or double-blinded randomized trials performed at one center or multiple centerstrials…all come to a similar conclusion that when the strictest quality tools and interpretation of heterogeneity are used, Level I evidence demonstrates that the use of HA in patients with OA results in modest improvement in pain.
![Page 40: Management of chronic knee pain](https://reader035.vdocuments.site/reader035/viewer/2022062523/5872dcee1a28ab74188b766d/html5/thumbnails/40.jpg)
• Ann Intern Med. 2012 Aug 7;157(3):180-91. doi: 10.7326/0003-4819-157-3-201208070-00473.
• Viscosupplementation for osteoarthritis of the knee: a systematic review and meta-analysis.
• In patients with knee osteoarthritis, viscosupplementation is associated with a small and clinically irrelevant benefit and an increased risk for serious adverse events.
Viscosupplement-Evidence
![Page 41: Management of chronic knee pain](https://reader035.vdocuments.site/reader035/viewer/2022062523/5872dcee1a28ab74188b766d/html5/thumbnails/41.jpg)
• Viscosupplementation with hyaluronic acid in the treatment for cartilage lesions: a review of current evidence and future directions
• European Journal of Orthopaedic Surgery & Traumatology;Feb2013, Vol. 23 Issue 2, p119
• With a very solid safety profile, viscosupplementation with hyaluronic acid (HA) derivatives has become an excellent modality for treating diseased articular cartilage. Recent literature supports the use of HA not only in the management of the pain associated with osteoarthritis but also as a disease-modifying agent as well.
Viscosupplement-Evidence
![Page 42: Management of chronic knee pain](https://reader035.vdocuments.site/reader035/viewer/2022062523/5872dcee1a28ab74188b766d/html5/thumbnails/42.jpg)
• Further studies have started to define exciting new roles for Viscosupplementation in the treatment for acute injuries to the joint microenvironment.
Viscosupplement-Evidence
![Page 43: Management of chronic knee pain](https://reader035.vdocuments.site/reader035/viewer/2022062523/5872dcee1a28ab74188b766d/html5/thumbnails/43.jpg)
Platelet rich plasma
• Platelets are crucial for tissue repair and vascular remodelling. The first stage of normal wound healing, immediately following injury or insult, is inflammation, where activated platelets adhere to the site of injury releasing growth factors .
• Platelet-rich plasma injections aim to promote cartilage repair and relieve osteoarthritic symptoms, potentially delaying the need for joint replacement surgery. Platelets produce growth factors that are thought to stimulate chondrocyte proliferation, leading to cartilage repair.
• Platelet-rich plasma injections for osteoarthritis of the knee» NICE interventional procedure guidance 491
guidance.nice.org.uk/ipg491-2014
![Page 44: Management of chronic knee pain](https://reader035.vdocuments.site/reader035/viewer/2022062523/5872dcee1a28ab74188b766d/html5/thumbnails/44.jpg)
Prolotherapy
• Prolotherapy stimulates local healing of chronically injured extra- and intra-articular tissue.
• Every 2-4 weeks for 3-6 months
![Page 45: Management of chronic knee pain](https://reader035.vdocuments.site/reader035/viewer/2022062523/5872dcee1a28ab74188b766d/html5/thumbnails/45.jpg)
Genicular Branch Neurotomy
Radiofrequency treatment relieves chronic knee osteoarthritis pain: a double-blind randomized controlled trial. Pain. 2011 Mar;152(3):481-7
![Page 46: Management of chronic knee pain](https://reader035.vdocuments.site/reader035/viewer/2022062523/5872dcee1a28ab74188b766d/html5/thumbnails/46.jpg)
Volume of evidence is great but quality of evidence is
poor
![Page 47: Management of chronic knee pain](https://reader035.vdocuments.site/reader035/viewer/2022062523/5872dcee1a28ab74188b766d/html5/thumbnails/47.jpg)
![Page 48: Management of chronic knee pain](https://reader035.vdocuments.site/reader035/viewer/2022062523/5872dcee1a28ab74188b766d/html5/thumbnails/48.jpg)
Epidemiology
• Prevalance• Common worldwide• 2-5% adult US population• 35-50 yrs
• Gender • Women > Men
![Page 49: Management of chronic knee pain](https://reader035.vdocuments.site/reader035/viewer/2022062523/5872dcee1a28ab74188b766d/html5/thumbnails/49.jpg)
Pathophysiology
• Central Pain Mechanism
• Central sensitization- generalized heightened pain sensitivity of FM patients
In Fibromyalgia there is increased activation of second order neurons in the spinal cord• There are two types of second order neurons:– Nociceptive specific neurons– Wide dynamic range neurons
Central sensitization of nociceptive neurons leads to nociceptive nerve impulses being perceived as morepainful (hyperalgesia)
• Central sensitization of wide dynamic range neurons leads to nonnociceptive nerve impulses being perceived as painful (allodynia)
![Page 50: Management of chronic knee pain](https://reader035.vdocuments.site/reader035/viewer/2022062523/5872dcee1a28ab74188b766d/html5/thumbnails/50.jpg)
An Official Diagnosis• Chronic Rheumatism• Fibrositis• Multiache Syndrome• Psychological Pain- “all in your head”
AMA recognized FMS as a TRUE ILLNESS- 1987
WHO -1993
www.ipscindia.com
![Page 51: Management of chronic knee pain](https://reader035.vdocuments.site/reader035/viewer/2022062523/5872dcee1a28ab74188b766d/html5/thumbnails/51.jpg)
Myofacial Pain Syndrome
• Myofascial pain syndrome is a chronic local/ regional musculo-skeletal pain disorder that may involve either a single muscle or a muscle group.
• No systemic features usually.
• The pain may be of a burning, stabbing, aching or nagging quality.
• Presence of trigger points in muscle belly.
www.ipscindia.com
![Page 52: Management of chronic knee pain](https://reader035.vdocuments.site/reader035/viewer/2022062523/5872dcee1a28ab74188b766d/html5/thumbnails/52.jpg)
Myofacial Trigger points
Trigger points are usually associated with a taut band, a ropey thickening of the muscle tissue. Trigger point, when pressed upon, will cause the pain to be felt elsewhere. This is what is considered "referred pain".
Electron microscopy confirmed these to be contracted sarcomere
![Page 53: Management of chronic knee pain](https://reader035.vdocuments.site/reader035/viewer/2022062523/5872dcee1a28ab74188b766d/html5/thumbnails/53.jpg)
Recent research
• Neurogenic Mediators at motor End Plate
Injured muscles
Local ischemia
Activate muscle receptors
Triggers the release of CGRP from muscle pain fibres
Increased motor endplate activity
Staud RPathogenesis of chronic muscle pain.Best Pract Res Clin Rheumatol.2007;21,3:581-596
![Page 54: Management of chronic knee pain](https://reader035.vdocuments.site/reader035/viewer/2022062523/5872dcee1a28ab74188b766d/html5/thumbnails/54.jpg)
Central sensitization
• Referred muscle pain is frequently hyperalgesic in nature
• Arendt-Nielsen L, Svensson P. Referred muscle pain: Basic and clinical findings. Clin J Pain. 2001; 17:11-19.
• Bennett R. Myofascial pain syndromes and their evaluation. Best Pract Res Clin Rheumatol. 2007; 21,3:427-445.
Clinical conditions that result from central sensitization:
• Hyperpathia • Allodynia • Hyperalgesia• Neuropathic Pain
![Page 55: Management of chronic knee pain](https://reader035.vdocuments.site/reader035/viewer/2022062523/5872dcee1a28ab74188b766d/html5/thumbnails/55.jpg)
MPS FMS• Local/ regional musculo-
skeletal pain disorder that may involve either a single muscle or a muscle group.
• Trigger points at ms belly.
• Usually no systemic symptoms.
• More common in males & curable.
• No genetic predisposition.
www.ipscindia.com
Systemic illness with widespread muscle pain.
Tender points at Ms. -Tendon junction.
Other systemic symptoms exists.
More common in females & seldom curable.
Genetic predisposition.
![Page 56: Management of chronic knee pain](https://reader035.vdocuments.site/reader035/viewer/2022062523/5872dcee1a28ab74188b766d/html5/thumbnails/56.jpg)
Clinical Presentation
FMS
www.ipscindia.com
![Page 57: Management of chronic knee pain](https://reader035.vdocuments.site/reader035/viewer/2022062523/5872dcee1a28ab74188b766d/html5/thumbnails/57.jpg)
Pieces to the Puzzle
www.ipscindia.com
![Page 58: Management of chronic knee pain](https://reader035.vdocuments.site/reader035/viewer/2022062523/5872dcee1a28ab74188b766d/html5/thumbnails/58.jpg)
Fibromyalgia
www.ipscindia.com
![Page 59: Management of chronic knee pain](https://reader035.vdocuments.site/reader035/viewer/2022062523/5872dcee1a28ab74188b766d/html5/thumbnails/59.jpg)
![Page 60: Management of chronic knee pain](https://reader035.vdocuments.site/reader035/viewer/2022062523/5872dcee1a28ab74188b766d/html5/thumbnails/60.jpg)
Clinical Presentation
MPS
![Page 61: Management of chronic knee pain](https://reader035.vdocuments.site/reader035/viewer/2022062523/5872dcee1a28ab74188b766d/html5/thumbnails/61.jpg)
• Pain- poorly localized, regional , aching
• Weakness and Fatigue
• Numbness, paresthesias
• Varying level of disability
• Autonomic dysfunction
![Page 62: Management of chronic knee pain](https://reader035.vdocuments.site/reader035/viewer/2022062523/5872dcee1a28ab74188b766d/html5/thumbnails/62.jpg)
Trigger points and Referral pattern
Iliopsoas
Longissimus
Quadratus
www.ipscindia.com
![Page 63: Management of chronic knee pain](https://reader035.vdocuments.site/reader035/viewer/2022062523/5872dcee1a28ab74188b766d/html5/thumbnails/63.jpg)
Trigger points and Referral pattern
Sternomastoid
Trapezius
Levator Scapula
Splenius capitiswww.ipscindia.com
![Page 64: Management of chronic knee pain](https://reader035.vdocuments.site/reader035/viewer/2022062523/5872dcee1a28ab74188b766d/html5/thumbnails/64.jpg)
classification
Primary
Concomittant
mildmoderatesevere
![Page 65: Management of chronic knee pain](https://reader035.vdocuments.site/reader035/viewer/2022062523/5872dcee1a28ab74188b766d/html5/thumbnails/65.jpg)
Diagnosis
www.ipscindia.com
![Page 66: Management of chronic knee pain](https://reader035.vdocuments.site/reader035/viewer/2022062523/5872dcee1a28ab74188b766d/html5/thumbnails/66.jpg)
Diagnosis• Clinical
• No characteristic Lab findings.
• Demonstrable biochemical abnormalities- Research Laboratory
• Substance P in CSF is three times higher in FMS.
• Low serotonin levels in platelets & CNS.• Low levels of ATP in RBC and trigger points. • Dysfunction of the HPA axis. • Low growth hormone.• Nerve growth factor was 4 times higher in
CSF.
www.ipscindia.com
![Page 67: Management of chronic knee pain](https://reader035.vdocuments.site/reader035/viewer/2022062523/5872dcee1a28ab74188b766d/html5/thumbnails/67.jpg)
f- MRI
www.ipscindia.com
![Page 68: Management of chronic knee pain](https://reader035.vdocuments.site/reader035/viewer/2022062523/5872dcee1a28ab74188b766d/html5/thumbnails/68.jpg)
Diagnostic Criteria
• Gowers (1904) -Diffuse pain as Fibrositis.– Histopathologicaly could not be proven.
• Hench (1976)- First clinical definition– Pain– No physiological explanation
• Smythe (1979)– Tender points
• Yunus (1981)- Develop critera– Diffuse pain > 3 months duration– Lack of other obvious cause
www.ipscindia.com
![Page 69: Management of chronic knee pain](https://reader035.vdocuments.site/reader035/viewer/2022062523/5872dcee1a28ab74188b766d/html5/thumbnails/69.jpg)
ACR Criteria (1990)• Widespread pain – 3 months
duration• Tenderness 11/18 tender points
Specificity-81%Sensitivity- 88%
Tender points = ESR
www.ipscindia.com
![Page 70: Management of chronic knee pain](https://reader035.vdocuments.site/reader035/viewer/2022062523/5872dcee1a28ab74188b766d/html5/thumbnails/70.jpg)
Symptom Intensity scale score -2010“No Tender Points”
www.ipscindia.comWolfe F, Rasker JJ. The Symptom Intensity Scale, fibromyalgia, and the meaning of fibromyalgia-like symptoms. J
Rheumatol 2006; 33:2291–2299
![Page 71: Management of chronic knee pain](https://reader035.vdocuments.site/reader035/viewer/2022062523/5872dcee1a28ab74188b766d/html5/thumbnails/71.jpg)
Symptom Intensity scale score
• Simple way to measure overall health
• Severity
• Can detect FMS in patients with other disease
• Uncovers comorbid depression
www.ipscindia.com